Combination therapy using a dual PPAR-a/PPAR-y activator and a GLP-1 derivative for the treatment of metabolic syndrome and related diseases and disorders
AssigneeNovo Nordisk A/S
InventorsJohn Patrick Mogensen, Per Sauerberg, Paul Stanley Bury, Lone Jeppesen, Ingrid Pettersson
Life of this patent
Estimating the term…
Abstract
The present invention relates to a pharmaceutical composition comprising a dual Peroxisome Proliferator-Activated Receptor-alpha/Peroxisome Proliferator-Activated Receptor-gama activator (PPAR-α/PPAR-γ) and a Glucagon Like Peptide-1 (GLP-1) derivative for treating, preventing and reducing the risk of developing Type 2 diabetes, insulin resistance, dyslipidemia, obesity, hypertension and other related diseases and disorders.
Claims72
A pharmaceutical composition comprising a glucagon like peptide-1 (GLP-1) derivative and a dual Peroxisome Proliferator-Activated Receptor-α/Peroxisome Proliferator-Activated Receptor-γ (PPAR-α/PPAR-γ) activator.
A process for making a pharmaceutical composition comprising combining a GLP-1 derivative and a dual PPAR-α/PPAR-γ activator and a pharmaceutically acceptable carrier.
A kit comprising an amount of a GLP-1 derivative and a pharmaceutically acceptable carrier, vehicle, or diluent in a first unit dosage form;
- an amount of a dual PPAR-α/PPAR-γ activator and a pharmaceutically acceptable carrier, vehicle, or diluent in a second unit dosage form;
- and a container.
A method for treating or preventing diseases or disorders involving the metabolic syndrome, insulin resistance, dyslipidemia, obesity, diabetes, hypertriglyceridaemia, impaired glucose tolerance or hypertension, said method comprising administering to a patient in need of said treatment (i) a first amount of a GLP-1 derivative and (ii) a second amount of a dual PPAR-α/PPAR-γ activator, wherein said first and second amounts together are effective for said treatment.
Dependencies are inferred from the claim text.